

Autoimmune Disorder

A study of the long-term effects of fenebrutinib treatment in patients with lupus

An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

| | | |
|-----------------------------------|--------------------------------------|--|
| Trial Status Terminated | Trial Runs In 11 Countries | Trial Identifier NCT03407482 2017-001764-37 GA30066 |
|-----------------------------------|--------------------------------------|--|

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase II, multicenter, open-label extension (OLE) study will evaluate the long-term safety and efficacy of GDC-0853 in participants with systemic lupus erythematosus (SLE) who have completed Study GA30044 (NCT02908100) up to 48 weeks.

| | |
|-----------------------------------|-------------------------|
| Genentech, Inc. Sponsor | Phase 2 Phase |
|-----------------------------------|-------------------------|

NCT03407482 2017-001764-37 GA30066
Trial Identifiers

Eligibility Criteria:

| | | |
|----------------------|---|---------------------------------|
| Gender All | Age >= 18 Years & <= 76 Years | Healthy Volunteers No |
|----------------------|---|---------------------------------|

This clinical trial was done to study a new medicine called, “fenebrutinib”, for the treatment of patients with “lupus”. Researchers wanted to know if fenebrutinib was safe over a long-term period when given to patients with lupus. One hundred and sixty patients took part in this study at 49 study centers in 11 countries.